


The background of the slide features a close-up, top-down view of several pills and a stethoscope. The pills are in various colors: white, yellow, and pink/red. Some are oval-shaped, while others are capsules. A silver stethoscope with a brown leather-like handle is positioned on the right side, its chest piece resting on a yellow pill. The overall lighting is soft and clinical.

Bakers Union and FELRA Health and Welfare Fund

Annual Review
January – December 2022

March 2, 2023

Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
 - Clinical Outcomes
 - Vigilant Outcomes
 - VCS Outcomes
7. Opportunity – Price Edge

Your OptumRx Team

Paul Marcus

VP, Client Management
Labor & Trust

Holly Agoney

Strategic Account Executive
Labor & Trust

Caroline Atwood

Director, Client
Management
Labor & Trust

Autumn Leblanc

Pharmacy Account
Manager
Labor & Trust

Fabian Gonzales

Pharmacy Service
Specialist
Labor & Trust

Current Plan Design

❑ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays			
Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

❑ Effective 7/1/19

- ❑ Diabetes Program
- ❑ Comprehensive Ums
- ❑ Vigilant Program
- ❑ RxOTC Program

❑ Effective 8/1/2020

- ❑ Orphan Drug Program

❑ Effective 3/1/2021

- ❑ Opioid Mgmt – tighter refill window & UMs

Plan 3 (group BFWRX3):		
	Retail / Mail	
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

❑ Effective 7/1/2021

- ❑ Premium Formulary
- ❑ Mandatory Mail (MSS)

❑ Effective 1/1/2022

- ❑ Split-fill/Smart-fill

❑ Effective 3/1/2022

- ❑ CCAA/VCS

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = 13.5% Specialty trend = negative -17.9%
- ❑ Specialty represents 1% of claims

- ❑ Top 5 disease states accounted for 74% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions


- ❑ Rebates – Jan – Dec 2022
 - ❑ Estimated - \$176,900

- ❑ Clinical Outcomes savings
 - ❑ **UM (PA, ST, QL)** – Jan – Dec 2022
 - ❑ Savings = \$84,300
 - ❑ **Vigilant** – Jan – Dec 2022
 - ❑ Savings = \$5,201
 - ❑ **VCS** – Jan – Dec 2022
 - ❑ Savings = \$8,532

Key Statistics

Key Statistics – Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -44.
- Number of utilizers has decreased by -84.

Total Rx's

CURRENT

7,906

PREVIOUS

8,587

PERCENT CHANGE

-7.9%

Total plan paid

CURRENT

\$912,440

PREVIOUS

\$860,678

PERCENT CHANGE

6.0%

Utilizers

CURRENT

462

PREVIOUS

546

PERCENT CHANGE

-15.4%

Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL


Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 13.5%, compared to the benchmark trend of 11.0%
- Member Paid Share changed by 5.1% period over period, compared to the benchmark of -6.5%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	43.2	42.2	2.4%	36.8	0.6%	36.9	0.4%
Plan paid PMPM	\$122.92	\$108.33	13.5%	\$109.72	11.0%	\$122.74	11.2%
Plan paid per Rx	\$115.41	\$100.23	15.1%	\$146.50	13.0%	\$147.29	11.5%
Rxs PMPM	1.085	1.081	-1.5%	0.749	-1.7%	0.833	-0.3%
Average days supply	29.4	27.2	7.8%	38.8	1.8%	38.5	2.1%
Days supply PMPM	31.3	29.4	6.2%	29.1	0.0%	32.1	1.8%
Member paid share	8.9%	8.5%	5.1%	10.0%	-6.5%	11.1%	-3.3%
Member paid per Rx	\$11.29	\$9.29	21.6%	\$16.38	4.8%	\$18.42	7.3%
Generic dispensing rate	82.2%	80.6%	2.0%	86.3%	2.4%	84.8%	1.9%
GDR-without Vaccines	86.0%	88.8%	-3.2%	88.9%	-0.4%	88.1%	-1.2%
Home delivery rate	5.0%	2.9%	73.1%	7.1%	2.6%	5.4%	0.9%
Retail 90 rate	1.4%	2.4%	-39.8%	15.3%	5.2%	18.4%	5.3%
Percent of specialty plan paid	20.6%	28.4%	-27.7%	47.0%	3.9%	50.6%	1.3%

Specialty Key Statistics

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -44.
- Number of utilizers has increased by 1.

Total Rx's

CURRENT

76

PREVIOUS

58

PERCENT CHANGE

31.0%

Total plan paid

CURRENT

\$187,716

PREVIOUS

\$244,772

PERCENT CHANGE

-23.3%

Utilizers

CURRENT

8

PREVIOUS

7

PERCENT CHANGE

14.3%

Specialty Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -17.9%, compared to the benchmark trend of 15.4%
- Member Paid Share changed by 1,261.4% period over period, compared to the benchmark of -8.9%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan Paid PMPM	\$25.29	\$30.81	-17.9%	\$51.57	15.4%	\$62.06	12.6%
Plan paid per Rx	\$2,469.94	\$4,220.20	-41.5%	\$6,121.05	7.8%	\$6,103.82	6.1%
Rxs PMPM	0.010	0.007	40.3%	0.008	7.0%	0.010	6.1%
Average days supply	28.8	28.7	0.3%	32.9	2.2%	32.5	1.2%
Days supply PMPM	0.3	0.2	40.6%	0.3	9.4%	0.3	7.4%
Member paid share	4.6%	0.3%	1,261.4%	5.6%	-8.9%	5.5%	6.0%
Member paid per Rx	\$119.11	\$14.31	732.3%	\$365.62	-2.3%	\$356.05	12.8%
Generic dispensing rate	47.4%	13.8%	243.4%	22.2%	-3.8%	20.3%	-6.5%
Home delivery rate	2.6%	12.1%	-78.2%	5.0%	-5.8%	3.8%	-5.2%
Retail 90 rate	0.0%	0.0%	0.0%	5.7%	20.2%	6.0%	7.7%


Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 13.5% over the previous period driven primarily by drug mix in traditional and drug mix for specialty.

Specialty represents 1.0% of claims.



+2.4% over benchmark



+18.5% over benchmark




-33.3% under benchmark

Traditional vs. Specialty Trend Components

Traditional trend: 25.9%

Benchmark comparison: LABOR AND TRUST


- Traditional trend contributed 137.8% to the overall trend (13.5%)
- Traditional accounts for 79.4% of overall total plan paid and was up from 71.6% in the prior period



Specialty trend: -17.9%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed -37.8% to the overall trend (13.5%)
- Specialty accounts for 20.6% of overall total plan paid and was down from 28.4% in the prior period




Top Disease States & Top 20 Drugs

Top Disease States

Top 5 disease states account for 74% of total Plan Paid

- Diabetes accounts for 27.4% of total plan paid, with trend driven by Utilization. TRULICITY was the top drug
- Inflammatory Conditions accounts for 19.5% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug

Sort by: Plan Paid



Top 20 Drugs by Plan Cost

All meds are Brands

Specialty

Rank													Trend components		
Cu	Pv	Benoh	Drug name	Therapy class	Utiliz	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Benoh plan paid PMPM	% Trend	Top driver	% Top driver
1	2	6	DUPIXENT	Chronic Inflammatory Disease	4	26	27.5	\$85,920	\$3,304.61	\$11.57	\$7.52	\$2.30	53.8%	Utiliz	56.0%
2	1	1	HUMIRA PEN	Chronic Inflammatory Disease	1	12	28.0	\$75,289	\$6,274.12	\$10.14	\$10.08	\$7.66	0.6%	Cost	6.7%
3	5	220	STRIBILD	HIV-Multiclass Combo	1	12	30.0	\$44,006	\$3,667.20	\$5.93	\$5.25	\$0.07	13.0%	Utiliz	7.0%
4	12	4	TRULICITY	★ GLP-1 Receptor Agonists	6	34	28.2	\$27,749	\$816.15	\$3.74	\$1.85	\$3.15	102.3%	Utiliz	103.4%
5	6	9	BIKTARVY	HIV-Multiclass Combo	1	8	30.0	\$26,597	\$3,324.65	\$3.58	\$3.16	\$1.70	13.4%	Utiliz	7.0%
6	7	35	VICTOZA	★ GLP-1 Receptor Agonists	2	20	39.0	\$26,208	\$1,310.40	\$3.53	\$2.84	\$0.56	24.5%	Utiliz	21.0%
7	11	5	JARDIANCE	★ SGLT-2 Inhibitors & Combos	7	49	30.0	\$25,520	\$520.81	\$3.44	\$1.96	\$2.88	75.6%	Utiliz	87.3%
8	19	32	SYMBICORT	Inhaled Asthma/COPD Combo	7	67	33.9	\$24,759	\$369.54	\$3.34	\$1.22	\$0.61	173.2%	Utiliz	179.3%
9	98	36	ADVAIR DISKUS	Inhaled Asthma/COPD Combo	6	48	31.2	\$19,379	\$403.73	\$2.61	\$0.18	\$0.52	1,344.2%	Utiliz	1,683.9%
10	13	22	JANUMET	★ DPP-4 Inhibitors & Combos	3	30	36.0	\$17,563	\$585.44	\$2.37	\$1.71	\$0.81	38.1%	Utiliz	32.9%
11	10	178	PREZCOBIX	HIV-Multiclass Combo	1	6	40.0	\$17,075	\$2,845.83	\$2.30	\$2.05	\$0.09	12.5%	Utiliz	7.0%
12	22	14	LANTUS SOLOSTAR	★ Insulin	10	35	38.2	\$14,937	\$426.76	\$2.01	\$0.90	\$1.37	122.6%	Utiliz	147.2%
13	17	28	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	18	40.0	\$14,105	\$783.62	\$1.90	\$1.40	\$0.65	35.7%	Utiliz	28.4%
14	-	11	TALTZ	Chronic Inflammatory Disease	1	2	28.0	\$13,038	\$6,519.08	\$1.76	\$0.00	\$1.55	-	-	-
15	31	112	NOVOLOG FLEXPEN	★ Insulin	6	20	43.5	\$13,006	\$650.29	\$1.75	\$0.61	\$0.18	185.9%	Utiliz	204.3%
16	14	3	OZEMPIC	★ GLP-1 Receptor Agonists	3	5	84.0	\$12,047	\$2,409.39	\$1.62	\$1.58	\$3.74	2.4%	Utiliz	-2.7%
17	67	33	TRELEGY ELLIPTA	Inhaled Asthma/COPD Combo	2	19	30.0	\$11,260	\$592.61	\$1.52	\$0.29	\$0.60	420.8%	Utiliz	408.4%
18	9	10	JANUVIA	★ DPP-4 Inhibitors & Combos	4	22	30.0	\$10,932	\$496.93	\$1.47	\$2.17	\$1.68	-32.2%	Utiliz	-35.6%
19	18	109	DEXILANT	Proton Pump Inhibitors	3	35	30.0	\$10,074	\$287.82	\$1.36	\$1.27	\$0.19	6.8%	Utiliz	7.0%
20	8	126	LANTUS	★ Insulin	5	16	29.6	\$9,828	\$614.22	\$1.32	\$2.50	\$0.15	-47.0%	Utiliz	-40.4%
Total					49	484	33.3	\$499,292	\$1,031.60	\$67.26	\$48.55	\$30.46	38.5%		62.3%
Plan Total					482	7,906	29.4	\$912,440	\$115.41	\$122.92	\$108.33	\$109.72	13.5%		6.2%

Rebates


Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Dec 2022

Benchmark: LABOR AND TRUST

Current rebate value: \$23.83 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$99.09, versus plan paid PMPM of \$122.92.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$108.42	\$10.81	\$97.63	\$19.29	\$78.34
Specialty	\$26.51	\$1.22	\$25.29	\$4.54	\$20.75
Total	\$134.93	\$12.03	\$122.92	\$23.83	\$99.09

Total estimated rebate yield for reporting period: **\$176.9K**

Rebate Performance by Disease State

Disease	Drug cost PMPM	Member paid PMPM	Plan paid PMPM	Rebate PMPM	Net plan paid PMPM	Rebate offset
Diabetes	\$35.61	\$1.96	\$33.66	\$9.01	\$24.65	26.6%
Inflammatory Conditions	\$25.20	\$1.20	\$24.00	\$4.54	\$19.46	18.9%
Asthma / COPD	\$13.42	\$0.68	\$12.74	\$3.00	\$9.74	23.5%
Diabetic Supplies	\$2.29	\$0.22	\$2.08	\$1.91	\$0.16	92.2%
Cardiovascular	\$10.08	\$1.97	\$8.11	\$1.17	\$6.95	14.4%
Ulcer/Acid Reflux/Gerd	\$1.88	\$0.18	\$1.70	\$0.74	\$0.96	43.7%
Blood Clot Prevention/Stroke Prevention	\$2.30	\$0.15	\$2.15	\$0.56	\$1.58	26.3%
HIV	\$12.62	\$0.33	\$12.28	\$0.55	\$11.73	4.5%
Gastrointestinal, Misc	\$1.49	\$0.07	\$1.41	\$0.36	\$1.05	25.7%
Cholesterol Lowering Agents	\$4.39	\$1.09	\$3.30	\$0.24	\$3.05	7.4%
Male And Female Hormone Replacement	\$0.84	\$0.07	\$0.77	\$0.23	\$0.53	30.5%
Ophthalmic Agents	\$1.32	\$0.08	\$1.24	\$0.21	\$1.03	17.0%
Overactive Bladder / Incontinence	\$0.96	\$0.04	\$0.91	\$0.19	\$0.72	21.3%
Contraception	\$1.49	\$0.03	\$1.45	\$0.19	\$1.26	13.2%
Glaucoma	\$1.20	\$0.05	\$1.15	\$0.15	\$1.00	13.0%
Antipsychotics	\$1.38	\$0.26	\$1.12	\$0.13	\$0.99	11.6%
Antibiotics	\$1.11	\$0.32	\$0.78	\$0.13	\$0.66	16.1%
Misc Skin Condition	\$1.79	\$0.18	\$1.61	\$0.11	\$1.50	6.7%
Severe Allergic Reaction	\$0.14	\$0.01	\$0.13	\$0.09	\$0.05	64.7%
Anti-Inflammatory (Steroids)	\$0.15	\$0.08	\$0.08	\$0.08	\$0.00	105.4%
Migraine/Pain Relief	\$0.38	\$0.06	\$0.32	\$0.06	\$0.26	19.6%
Misc Mental Disorders	\$0.02	\$0.00	\$0.02	\$0.04	-\$0.02	198.6%
Ear Condition	\$0.27	\$0.02	\$0.24	\$0.04	\$0.20	17.9%
Narcotic Analgesics	\$0.23	\$0.11	\$0.12	\$0.04	\$0.08	33.0%
Topical Anti-Fungal	\$0.30	\$0.07	\$0.23	\$0.02	\$0.21	9.4%
Seizure Disorders	\$1.51	\$0.27	\$1.25	\$0.02	\$1.23	1.7%


Clinical Outcomes

UM Outcomes

Utilization management savings: \$11.36 PMPM

Your program savings: **\$84.3K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$84.3K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.



Outcomes date range: Jul 2021 - Jun 2022

Prior authorization

PMPM SAVINGS

\$3.25

NUMBER OF MEMBERS IMPACTED

40

NUMBER OF INTERVENTIONS

51

Quantity limits

PMPM SAVINGS

\$5.43

NUMBER OF MEMBERS IMPACTED

8

NUMBER OF INTERVENTIONS

9

Step therapy

PMPM SAVINGS

\$2.68

NUMBER OF MEMBERS IMPACTED

78

NUMBER OF INTERVENTIONS

90

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Dec 2022

Total program savings: \$0.70 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$5.2K in pharmacy spend
- Switched 9 claims to lower cost alternatives
- 8 claims were abandoned



TOTAL PLAN PAID SAVINGS
\$5,201

TOTAL PROGRAM SAVINGS
0.6%

TOTAL MEMBERS IMPACTED
17

Savings by Vigilant Drug List

Sort by: Members impacted

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	\$0.34	8	8
Clinical Duplicates	\$0.11	3	3
High Cost Brands with Generics	\$0.00	2	2
Non-FDA Approved Drugs	\$0.07	2	2
Creams & Patches	\$0.04	1	1
New Drugs to Market	\$0.14	1	1

VCS Copay Solutions Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Dec 2022



Total program savings: \$1.15 PMPM

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$8,532 in Plan Paid savings
- \$609.43 average Plan Paid per impacted prescription
- 4 total impacted utilizers
- 14 prescriptions processed through the program out of a possible 29 eligible prescriptions

PLAN PAID SAVINGS

\$8,532

PLAN PAID SAVINGS PER IMPACTED RX

\$609.43

Top 5 drugs based on: Plan paid savings

DUPIXENT

IMPACTED RXS

4

IMPACTED UTILIZERS

2

PLAN PAID SAVINGS

\$4,332

HUMIRA PEN

IMPACTED RXS

8

IMPACTED UTILIZERS

1

PLAN PAID SAVINGS

\$4,000

TALTZ

IMPACTED RXS

2

IMPACTED UTILIZERS

1

PLAN PAID SAVINGS

\$200

Opportunity Price Edge

Price Edge

Claims Analysis: Bakers Union (10/1/21 - 09/30/22)

OptumRx Price Edge – Covered Generics

Of total claims, we found that a cash market price was lower than member cost share **34%** of the time (2k claims of 6k total paid claims), creating **\$5k of value to Bakers Union members**

Pharmacy Channel	Total Claims	Member Savings with Price Edge
Mail	326	\$ 297
Retail 30	5,932	\$ 4,485
Retail 90	70	
Total	6,328	\$ 4,782

OptumRx Price Edge – Non-covered Generics

Of total claims, we found **~160** of rejected claims that would be eligible for our direct-to-consumer discount through Price Edge.

Member savings can be as much as 85% off retail price, with the average member savings about 47%*

*Analysis done using 2021-2022 calendar year claims data

- A simple way to save on non-specialty generic drugs, covered or not.
- Our claim system scans discount card market pricing and compares it to the benefit – giving members a competitive price.
- Retains history for drug and clinical programs


Appendix

Trend Components

Total trend: **13.5%**

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 13.5% was 2.4% higher than benchmark
- Traditional spend influenced the trend contributing 137.8% (100.8% higher than benchmark)
- Specialty trend contributed -37.8% (100.8% lower than benchmark)



Top 20 traditional

All meds are Brands

Rank														Trend components		
Cu ↑	Pv ↓	Benoh ↓	Drug name ↑	Therapy class ↑	Utiliz ↓	Rxs ↓	Avg daily supply ↓	Total plan paid ↓	Plan paid per Rx ↓	Curr plan paid PMPM ↓	Prev plan paid PMPM ↓	Benoh plan paid PMPM ↓	% Trend ↓	Top driver ↓	% Top driver ↓	
1	1	115	STRIBILD	HIV-Multiclass Combo	1	12	30.0	\$44,006	\$3,667.20	\$5.93	\$5.25	\$0.07	13.0%	Utiliz	7.0%	
2	8	2	TRULICITY	GLP-1 Receptor Agonists	6	34	28.2	\$27,749	\$816.15	\$3.74	\$1.85	\$3.15	102.3%	Utiliz	103.4%	
3	2	5	BIKTARVY	HIV-Multiclass Combo	1	8	30.0	\$26,597	\$3,324.65	\$3.58	\$3.16	\$1.70	13.4%	Utiliz	7.0%	
4	3	18	VICTOZA	★ GLP-1 Receptor Agonists	2	20	39.0	\$26,208	\$1,310.40	\$3.53	\$2.84	\$0.56	24.5%	Utiliz	21.0%	
5	7	3	JARDIANCE	★ SGLT-2 Inhibitors & Combos	7	49	30.0	\$25,520	\$520.81	\$3.44	\$1.96	\$2.88	75.6%	Utiliz	87.3%	
6	15	16	SYMBICORT	Inhaled Asthma/COPD Combo	7	67	33.9	\$24,759	\$369.54	\$3.34	\$1.22	\$0.61	173.2%	Utiliz	179.3%	
7	92	19	ADVAIR DISKUS	Inhaled Asthma/COPD Combo	6	48	31.2	\$19,379	\$403.73	\$2.61	\$0.18	\$0.52	1,344.2%	Utiliz	1,683.9%	
8	9	12	JANUMET	★ DPP-4 Inhibitors & Combos	3	30	36.0	\$17,563	\$585.44	\$2.37	\$1.71	\$0.81	38.1%	Utiliz	32.9%	
9	6	94	PREZCOBIX	HIV-Multiclass Combo	1	6	40.0	\$17,075	\$2,845.83	\$2.30	\$2.05	\$0.09	12.5%	Utiliz	7.0%	
10	18	8	LANTUS SOLOSTAR	Insulin ★	10	35	38.2	\$14,937	\$426.76	\$2.01	\$0.90	\$1.37	122.6%	Utiliz	147.2%	
11	13	14	ENTRESTO	Angiotensin II Receptor & Natriuretic Peptide Receptor (ARNI)	2	18	40.0	\$14,105	\$783.62	\$1.90	\$1.40	\$0.65	35.7%	Utiliz	28.4%	
12	27	65	NOVOLOG FLEXPEN	★ Insulin	6	20	43.5	\$13,006	\$650.29	\$1.75	\$0.61	\$0.18	185.9%	Utiliz	204.3%	
13	10	1	OZEMPIC	★ GLP-1 Receptor Agonists	3	5	84.0	\$12,047	\$2,409.39	\$1.62	\$1.58	\$3.74	2.4%	Utiliz	-2.7%	
14	62	17	TRELEGY ELLIPTA	Inhaled Asthma/COPD Combo	2	19	30.0	\$11,260	\$592.61	\$1.52	\$0.29	\$0.60	420.8%	Utiliz	408.4%	
15	5	6	JANUVIA	★ DPP-4 Inhibitors & Combos	4	22	30.0	\$10,932	\$496.93	\$1.47	\$2.17	\$1.68	-32.2%	Utiliz	-35.6%	
16	14	63	DEXLANT	Proton Pump Inhibitors	3	35	30.0	\$10,074	\$287.82	\$1.36	\$1.27	\$0.19	6.8%	Utiliz	7.0%	
17	4	72	LANTUS	★ Insulin	5	16	29.6	\$9,828	\$614.22	\$1.32	\$2.50	\$0.15	-47.0%	Utiliz	-40.4%	
18	12	769	HUMALOG MIX 50/50 KWIKPEN	★ Insulin	1	4	90.0	\$9,611	\$2,402.78	\$1.29	\$1.47	\$0.01	-12.1%	Utiliz	-7.4%	
19	33	24	BREO ELLIPTA	Inhaled Asthma/COPD Combo	2	26	30.0	\$9,103	\$350.13	\$1.23	\$0.52	\$0.39	135.2%	Utiliz	131.9%	
20	16	58	BYDUREON BCISE	★ GLP-1 Receptor Agonists	1	12	28.5	\$8,995	\$749.58	\$1.21	\$1.19	\$0.20	1.5%	Cost	0.9%	
Total					47	486	33.9	\$362,764	\$725.83	\$47.52	\$34.13	\$19.55	39.2%		61.7%	
Plan Total					462	7,830	29.4	\$724,724	\$92.56	\$97.63	\$77.52	\$58.15	25.9%		13.5%	

Top 20 specialty

B = Brands
G = Generics

Rank														Trend components		
Cu ^Δ	Pv ^Δ	Bench ^Δ	Drug name ^Δ	Therapy class ^Δ	Utiliz ^Δ	Rxs ^Δ	Avg days supply ^Δ	Total plan paid ^Δ	Plan paid per Rx ^Δ	Curr plan paid PMPM ^Δ	Prev plan paid PMPM ^Δ	Bench plan paid PMPM ^Δ	% Trend ^Δ	Top driver ^Δ	% Top driver ^Δ	
1	2	3	DUPIXENT ^B	Chronic Inflammatory Disease	4	26	27.5	\$85,920	\$3,304.61	\$11.57	\$7.52	\$2.30	53.8%	Utiliz	56.0%	
2	1	1	HUMIRA.PEN ^B	Chronic Inflammatory Disease	1	12	28.0	\$75,289	\$6,274.12	\$10.14	\$10.08	\$7.66	0.6%	Cost	6.7%	
3	-	5	TALTZ ^B	Chronic Inflammatory Disease	1	2	28.0	\$13,038	\$6,519.08	\$1.76	\$0.00	\$1.55	-	-	-	
4	5	158	MYCOPHENCLATE MCFETIL ^G	Transplant	1	12	30.0	\$5,886	\$490.52	\$0.79	\$0.30	\$0.05	160.2%	Cost	97.4%	
5	3	10	OTEZLA ^B	Chronic Inflammatory Disease	2	0	0.0	\$3,941	\$0.00	\$0.53	\$6.48	\$1.11	-91.8%	Utiliz	-100.0%	
6	-	155	TACROLIMUS ^G	Transplant	1	24	30.0	\$3,642	\$151.73	\$0.49	\$0.00	\$0.05	-	-	-	
Total						8	76	28.8	\$187,716	\$2,469.94	\$25.29	\$30.81	\$14.21	-17.9%		-42.3%
Plan Total						8	76	28.8	\$187,716	\$2,469.94	\$25.29	\$30.81	\$61.57	-17.9%		-42.3%

4 out of the top 6 are for Chronic Inflammatory Disease

4 out of the top 6 have moved up in rank